Open Payments

Hospital For Special Surgery

Type
Teaching hospital
Where
New York, NY
Medicare CCN
330270
Received
$4,382,119 in 447 records, 2021 ($2,060,695 general, $2,321,424 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2021General payment224$2,060,695
2021Research payment223$2,321,424

By company

CompanyRecordsAmountYears
Gilead Sciences, Inc.5$760,4152021
EXACTECH, INC.8$566,0332021
Smith+Nephew, Inc.63$381,6012021
Stryker Corporation53$343,4502021
Zimmer Biomet Holdings, Inc.35$299,0132021
NuVasive, Inc.6$259,5002021
Medical Device Business Services, Inc.52$222,2772021
Regeneron Pharmaceuticals, Inc.4$175,1662021
Siemens Medical Solutions USA, Inc.2$163,9832021
UCB SA44$162,7732021
Medtronic, Inc.4$108,3772021
Radius Health, Inc.1$90,1132021
Avanos Medical1$79,5002021
Limacorporate S.p.A.3$72,3402021
GE HEALTHCARE2$63,3452021
Amgen Inc.3$49,7202021
Takeda Pharmaceuticals U.S.A., Inc.21$45,6002021
DePuy Synthes Products, Inc.4$44,8172021
Kadmon Corporation LLC3$44,1942021
Synthes GmbH2$38,0002021
AstraZeneca UK Limited2$28,9092021
SI-BONE, INC.9$28,8402021
E.R. Squibb & Sons, L.L.C.2$27,1042021
Lima USA, Inc.3$25,6272021
PFIZER INC.1$25,0002021
Alexion Pharmaceuticals, Inc.21$22,5272021
Joint Restoration Foundation, Inc.1$20,8262021
Apos US Management Inc.1$20,5642021
UOC USA INC2$19,5252021
DJO, LLC1$18,7142021
CSL Behring6$17,8292021
TREACE MEDICAL CONCEPTS, INC.3$16,4772021
Horizon Therapeutics plc1$14,4002021
Linvatec Corporation1$13,5262021
Ortho Development Corporation12$11,7152021
Arthrex, Inc.2$10,6002021
Globus Medical, Inc.2$10,0002021
SANOFI US SERVICES INC.4$9,5892021
Xiros Inc2$9,2972021
Engage Uni, LLC2$8,8792021
C. R. Bard, Inc. & Subsidiaries2$8,6412021
Boehringer Ingelheim Pharmaceuticals, Inc.1$7,5562021
Johnson & Johnson Health Care Systems Inc.9$6,7242021
ILLUMINOSS MEDICAL, INC.1$5,0442021
Novartis Pharmaceuticals Corporation1$4,3502021
Orion Corporation2$4,0042021
Masimo Corporation11$3,3032021
MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC.1$2,7502021
Abbott Laboratories2$2,3902021
Boehringer Ingelheim Pharma GmbH & Co.KG13$2,1252021

By nature of payment

NatureRecordsAmount
Research payment223$2,321,424
Grant69$683,017
Royalty or License17$549,778
Space rental or facility fees (teaching hospital only)77$481,165
Consulting Fee6$202,585
Compensation for services other than consulting, including serving as faculty or as a speaker at a v21$71,570
Education1$25,000
Long term medical supply or device loan19$23,564
Charitable Contribution1$13,552
Debt forgiveness13$10,461

Records

DateCompanyAmountNatureFormProductStudyYear
2021-12-31AstraZeneca UK Limited$8,450Research paymentIn-kind items and servicesSAPHNELO Biological, Inflammation and AutoimmunityThe purpose of this study is to characterise longterm safety and tolerability of intravenous anifrolumab A Multicentre R2021
2021-12-31SI-BONE, INC.$6,710Research paymentCash or cash equivalentIFUSE IMPLANT Device, SACROILIAC JOINT DYSFUNCTIONSILVIA2021
2021-12-31SI-BONE, INC.$4,860Research paymentCash or cash equivalentIFUSE IMPLANT Device, SACROILIAC JOINT DYSFUNCTIONSILVIA2021
2021-12-31SI-BONE, INC.$4,235Research paymentCash or cash equivalentIFUSE IMPLANT Device, SACROILIAC JOINT DYSFUNCTIONSILVIA2021
2021-12-31SI-BONE, INC.$3,955Research paymentCash or cash equivalentIFUSE IMPLANT Device, SACROILIAC JOINT DYSFUNCTIONSILVIA2021
2021-12-31SI-BONE, INC.$2,945Research paymentCash or cash equivalentIFUSE IMPLANT Device, SACROILIAC JOINT DYSFUNCTIONSILVIA2021
2021-12-31SI-BONE, INC.$2,745Research paymentCash or cash equivalentIFUSE IMPLANT Device, SACROILIAC JOINT DYSFUNCTIONSILVIA2021
2021-12-31SI-BONE, INC.$1,770Research paymentCash or cash equivalentIFUSE IMPLANT Device, SACROILIAC JOINT DYSFUNCTIONSILVIA2021
2021-12-31SI-BONE, INC.$810Research paymentCash or cash equivalentIFUSE IMPLANT Device, SACROILIAC JOINT DYSFUNCTIONSILVIA2021
2021-12-31SI-BONE, INC.$810Research paymentCash or cash equivalentIFUSE IMPLANT Device, SACROILIAC JOINT DYSFUNCTIONSILVIA2021
2021-12-31Stryker Corporation$546Debt forgivenessCash or cash equivalent2021
2021-12-31Masimo Corporation$1Long term medical supply or device loanIn-kind items and servicesSET and rainbow SET Device, Devices2021
2021-12-31Masimo Corporation$1Long term medical supply or device loanIn-kind items and servicesSET and rainbow SET Device, Devices2021
2021-12-31Masimo Corporation$1Long term medical supply or device loanIn-kind items and servicesSET and rainbow SET Device, Devices2021
2021-12-31Masimo Corporation$0Long term medical supply or device loanIn-kind items and servicesSET and rainbow SET Device, Devices2021
2021-12-31Masimo Corporation$0Long term medical supply or device loanIn-kind items and servicesSET and rainbow SET Device, Devices2021
2021-12-31Masimo Corporation$0Long term medical supply or device loanIn-kind items and servicesSET and rainbow SET Device, Devices2021
2021-12-31Masimo Corporation$0Long term medical supply or device loanIn-kind items and servicesSET and rainbow SET Device, Devices2021
2021-12-31Masimo Corporation$0Long term medical supply or device loanIn-kind items and servicesSedLine Device, Devices2021
2021-12-31Masimo Corporation$0Long term medical supply or device loanIn-kind items and servicesSedLine Device, Devices2021
2021-12-31Masimo Corporation$0Long term medical supply or device loanIn-kind items and servicesSedLine Device, Devices2021
2021-12-28E.R. Squibb & Sons, L.L.C.$13,552Charitable ContributionCash or cash equivalent2021
2021-12-28E.R. Squibb & Sons, L.L.C.$13,552GrantCash or cash equivalent2021
2021-12-24Amgen Inc.$25,000EducationCash or cash equivalent2021
2021-12-23DePuy Synthes Products, Inc.$11,565Royalty or LicenseCash or cash equivalent2021
2021-12-23Medical Device Business Services, Inc.$2,000GrantCash or cash equivalent2021
2021-12-22Zimmer Biomet Holdings, Inc.$5,850Space rental or facility fees (teaching hospital only)Cash or cash equivalentJuggerknot-Sports Medicine Device, Sports Medicine2021
2021-12-22Johnson & Johnson Health Care Systems Inc.$545Debt forgivenessIn-kind items and services2021
2021-12-22UCB SA$67Research paymentCash or cash equivalentPhase 3, Multicenter, Randomized, Double-Blind, PBO-Controlled Study of Efficacy, Safety, and Tolerability of Zilucoplan2021
2021-12-21SANOFI US SERVICES INC.$2,905Research paymentCash or cash equivalentREZUROCK Drug, OncologyA Phase 2 Randomized Placebo controlled Double blind Open label Extension Multicenter Study to Evaluate the Efficacy and2021
2021-12-16PFIZER INC.$25,000GrantCash or cash equivalent2021
2021-12-16Stryker Corporation$21,791Research paymentCash or cash equivalentT2 Device, TRAUMA & EXTREMETIESMETAL ION LEVELS IN STRYKER TRIDENT II TRITANIUM SYSTEM WITH MDM LINER, CERAMIC HEAD, AND ACCOLADE II OR SECURFIT ADVANC2021
2021-12-16Medical Device Business Services, Inc.$10,000GrantCash or cash equivalent2021
2021-12-16Medical Device Business Services, Inc.$10,000GrantCash or cash equivalent2021
2021-12-16Stryker Corporation$5,685Space rental or facility fees (teaching hospital only)Cash or cash equivalent2021
2021-12-16Smith+Nephew, Inc.$4,465Space rental or facility fees (teaching hospital only)Cash or cash equivalentLENS Device, Sports Med Visualization2021
2021-12-16Medical Device Business Services, Inc.$1,250GrantCash or cash equivalent2021
2021-12-15Takeda Pharmaceuticals U.S.A., Inc.$2,005Research paymentCash or cash equivalentHYQVIA Biological, IMMUNOLOGYTHIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND 2021
2021-12-15Takeda Pharmaceuticals U.S.A., Inc.$1,660Research paymentCash or cash equivalentHYQVIA Biological, IMMUNOLOGYTHIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND 2021
2021-12-15Takeda Pharmaceuticals U.S.A., Inc.$1,024Research paymentCash or cash equivalentHYQVIA Biological, IMMUNOLOGYTHIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND 2021
2021-12-15Ortho Development Corporation$824Royalty or LicenseCash or cash equivalentPagoda Device, ORTHOPEDIC DEVICE2021
2021-12-09Horizon Therapeutics plc$14,400Research paymentCash or cash equivalentUPLIZNA Drug, UPLIZNAVIB0551.P3.S12021
2021-12-09UCB SA$270Research paymentCash or cash equivalentAN OPEN-LABEL EXTENSION STUDY TO EVALUATE ROZANOLIXIZUMAB IN STUDY PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS2021
2021-12-08Zimmer Biomet Holdings, Inc.$5,518Space rental or facility fees (teaching hospital only)Cash or cash equivalentArcos Device, Hips2021
2021-12-08Zimmer Biomet Holdings, Inc.$3,000GrantCash or cash equivalentGrants Device, General2021
2021-12-03SANOFI US SERVICES INC.$3,411Research paymentCash or cash equivalentREZUROCK Drug, OncologyA Phase 2 Randomized Placebo controlled Double blind Open label Extension Multicenter Study to Evaluate the Efficacy and2021
2021-12-03SANOFI US SERVICES INC.$1,975Research paymentCash or cash equivalentREZUROCK Drug, OncologyA Phase 2 Randomized Placebo controlled Double blind Open label Extension Multicenter Study to Evaluate the Efficacy and2021
2021-12-03SANOFI US SERVICES INC.$1,296Research paymentCash or cash equivalentREZUROCK Drug, OncologyA Phase 2 Randomized Placebo controlled Double blind Open label Extension Multicenter Study to Evaluate the Efficacy and2021
2021-12-02Stryker Corporation$19,065Research paymentCash or cash equivalentTRIATHLON Device, KNEESMAVRIC MAGNETIC RESONANCE IMAGING USED TO STUDY DETAILED BONE APPOSITION AND FIXATION OF THE STRYKER TRIATHLON CEMENTLES2021
2021-12-02Stryker Corporation$19,065Research paymentCash or cash equivalentTRIATHLON Device, KNEESMAVRIC MAGNETIC RESONANCE IMAGING USED TO STUDY DETAILED BONE APPOSITION AND FIXATION OF THE STRYKER TRIATHLON CEMENTLES2021
2021-12-02Stryker Corporation$19,065Research paymentCash or cash equivalentTRIATHLON Device, KNEESMAVRIC MAGNETIC RESONANCE IMAGING USED TO STUDY DETAILED BONE APPOSITION AND FIXATION OF THE STRYKER TRIATHLON CEMENTLES2021
2021-12-02Stryker Corporation$12,710Research paymentCash or cash equivalentTRIATHLON Device, KNEESMAVRIC MAGNETIC RESONANCE IMAGING USED TO STUDY DETAILED BONE APPOSITION AND FIXATION OF THE STRYKER TRIATHLON CEMENTLES2021
2021-12-02Stryker Corporation$145Research paymentCash or cash equivalentRESTORATION Device, HIPSRESTORATION; ANATOMIC DUAL MOBILITY (ADM) X3; ACETABULAR SYSTEM STUDY WITH LONG TERM DATA COLLECTION FOR THE ACCOLADE; I2021
2021-12-01Boehringer Ingelheim Pharma GmbH & Co.KG$114Research paymentIn-kind items and servicesOFEV Drug, RESPIRATORYExtension2021
2021-12-01Johnson & Johnson Health Care Systems Inc.$26Debt forgivenessIn-kind items and services2021
2021-11-30Apos US Management Inc.$20,564Research paymentCash or cash equivalentAposHealth Device, MusculoskeletalApos knee pain2021
2021-11-30Medical Device Business Services, Inc.$500Research paymentCash or cash equivalentKincise Device, Ortho-HipProspective Randomized Multi Center Post Market study of Anterior Advantage Surgical Approach in Total Hip Arthroplasty 2021
2021-11-24Smith+Nephew, Inc.$715Research paymentCash or cash equivalentFAST-FIX FLEX Device, Sports Med KneeA Prospective, Multi-Center Clinical Study to Evaluate the Safety and Performance of the Fast-Fix Flex System for Menisc2021
2021-11-24Alexion Pharmaceuticals, Inc.$50Research paymentCash or cash equivalentA Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravuli2021
2021-11-18Siemens Medical Solutions USA, Inc.$150,000Research paymentCash or cash equivalentHSS_Potter_MSK_Clinical_MR_20212021
2021-11-18Stryker Corporation$194Research paymentCash or cash equivalentTRIDENT Device, HIPSTRIDENT II TRITANIUM OUTCOMES STUDY2021
2021-11-17Smith+Nephew, Inc.$4,719Space rental or facility fees (teaching hospital only)Cash or cash equivalentREDAPT Device, Recon Hips2021
2021-11-17Smith+Nephew, Inc.$4,504Space rental or facility fees (teaching hospital only)Cash or cash equivalentJOURNEY UNI Device, Recon Knees2021
2021-11-17Smith+Nephew, Inc.$3,020Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentJOURNEY UNI Device, Recon Knees2021
2021-11-17Smith+Nephew, Inc.$2,480Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREDAPT Device, Recon Hips2021
2021-11-15Ortho Development Corporation$1,613Royalty or LicenseCash or cash equivalentPagoda Device, ORTHOPEDIC DEVICE2021
2021-11-15Takeda Pharmaceuticals U.S.A., Inc.$250Research paymentCash or cash equivalentHYQVIA Biological, IMMUNOLOGYTHIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND 2021
2021-11-10Smith+Nephew, Inc.$23,166Research paymentCash or cash equivalentOR3O Device, Recon HipsProspective Multi-Center study to evaluate the safety and effectiveness of the OR30 Dual Mobility system in primary and 2021
2021-11-10Stryker Corporation$8,671Research paymentCash or cash equivalentMAKO Device, KNEES, HIPSALIGNMENT AND CLINICAL OUTCOMES OF ROBOTIC ARM ASSISTED TOTAL KNEE ARTHROPLASTY2021
2021-11-10Smith+Nephew, Inc.$2,261Research paymentCash or cash equivalentOR3O Device, Recon HipsProspective Multi-Center study to evaluate the safety and effectiveness of the OR30 Dual Mobility system in primary and 2021
2021-11-09UCB SA$8,208Research paymentCash or cash equivalentPhase 3, Multicenter, Randomized, Double-Blind, PBO-Controlled Study of Efficacy, Safety, and Tolerability of Zilucoplan2021
2021-11-09UCB SA$2,011Research paymentCash or cash equivalentPhase 3, Multicenter, Randomized, Double-Blind, PBO-Controlled Study of Efficacy, Safety, and Tolerability of Zilucoplan2021
2021-11-09UCB SA$191Research paymentCash or cash equivalentPhase 3, Multicenter, Randomized, Double-Blind, PBO-Controlled Study of Efficacy, Safety, and Tolerability of Zilucoplan2021
2021-11-08Smith+Nephew, Inc.$10,084Research paymentCash or cash equivalentOR3O Device, Recon HipsProspective Multi-Center study to evaluate the safety and effectiveness of the OR30 Dual Mobility system in primary and 2021
2021-11-08Medical Device Business Services, Inc.$6,532Space rental or facility fees (teaching hospital only)Cash or cash equivalent2021
2021-11-08Medical Device Business Services, Inc.$6,500Research paymentCash or cash equivalentACTIS Device, Ortho-HipActis Total Hip System 2 Year Follow up2021
2021-11-08Medical Device Business Services, Inc.$5,310Space rental or facility fees (teaching hospital only)Cash or cash equivalent2021
2021-11-08Medical Device Business Services, Inc.$3,000GrantCash or cash equivalent2021
2021-11-08Smith+Nephew, Inc.$1,670Research paymentCash or cash equivalentREDAPT Device, Recon HipsA Multicenter, Post Market Clinical Follow-up Study of Subjects with the REDAPT Revision Monolithic Sleeveless Stem and/2021
2021-11-08UCB SA$263Research paymentCash or cash equivalentA RANDOMIZED, OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF ROZANOLIXIZU2021
2021-11-05Siemens Medical Solutions USA, Inc.$13,983GrantIn-kind items and services2021
2021-11-05TREACE MEDICAL CONCEPTS, INC.$5,972Space rental or facility fees (teaching hospital only)Cash or cash equivalentLapiplasty System Device, Y2021
2021-11-04Medtronic, Inc.$26,688Research paymentCash or cash equivalentInvestigator Sponsored Research2021
2021-11-04Medtronic, Inc.$26,688Research paymentCash or cash equivalentInvestigator Sponsored Research2021
2021-11-04Stryker Corporation$9,555Research paymentCash or cash equivalentMAKO Device, KNEES, HIPSSURVIVORSHIP AND OUTCOMES OF ROBOTIC ARM ASSISTED MEDIAL UKA2021
2021-11-04Stryker Corporation$9,555Research paymentCash or cash equivalentMAKO Device, KNEES, HIPSSURVIVORSHIP AND OUTCOMES OF ROBOTIC ARM ASSISTED MEDIAL UKA2021
2021-11-04Stryker Corporation$4,465Space rental or facility fees (teaching hospital only)Cash or cash equivalentMAKO Device, KNEES, HIPS2021
2021-11-04Kadmon Corporation LLC$3,956Research paymentIn-kind items and servicesA Phase 2 Randomized Placebo controlled Double blind Open label Extension Multicenter Study to Evaluate the Efficacy and2021
2021-11-03Smith+Nephew, Inc.$1,670Research paymentCash or cash equivalentFAST-FIX FLEX Device, Sports Med KneeA Prospective, Multi-Center Clinical Study to Evaluate the Safety and Performance of the Fast-Fix Flex System for Menisc2021
2021-11-03Alexion Pharmaceuticals, Inc.$250Research paymentCash or cash equivalentA Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension 2021
2021-11-03Johnson & Johnson Health Care Systems Inc.$46Debt forgivenessIn-kind items and services2021
2021-11-03Johnson & Johnson Health Care Systems Inc.$1Debt forgivenessIn-kind items and services2021
2021-11-01Boehringer Ingelheim Pharma GmbH & Co.KG$116Research paymentIn-kind items and servicesOFEV Drug, RESPIRATORYExtension2021
2021-10-29Medical Device Business Services, Inc.$4,381Space rental or facility fees (teaching hospital only)Cash or cash equivalent2021
2021-10-28Smith+Nephew, Inc.$1,670Research paymentCash or cash equivalentBIRMINGHAM HIP Device, Recon HipsA Post-Approval Study of the Birmingham Hip Resurfacing (BHR) Radiological System Review2021
2021-10-28Stryker Corporation$1,475Research paymentCash or cash equivalentRESTORATION Device, HIPSRESTORATION; ANATOMIC DUAL MOBILITY (ADM) X3; ACETABULAR SYSTEM STUDY WITH LONG TERM DATA COLLECTION FOR THE ACCOLADE; I2021
2021-10-27Medical Device Business Services, Inc.$300Research paymentCash or cash equivalentACTIS Device, Ortho-HipActis Total Hip System 2 Year Follow up2021
2021-10-26UCB SA$816Research paymentIn-kind items and servicesA DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED, 18 MONTH PHASE 2A STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, 2021
2021-10-21UCB SA$13,947Research paymentCash or cash equivalentA RANDOMIZED, OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF ROZANOLIXIZU2021
2021-10-21UCB SA$6,693Research paymentCash or cash equivalentA PHASE 3, RANDOMIZED, DOUBL-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING EFFICACY AND SAFETY OF ROZANOLIXIZUMAB IN ADULT 2021
2021-10-21Smith+Nephew, Inc.$4,283Space rental or facility fees (teaching hospital only)Cash or cash equivalentWEREWOLF Device, Sports Med Resection2021
2021-10-21Smith+Nephew, Inc.$878Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentWEREWOLF Device, Sports Med Resection2021
2021-10-20AstraZeneca Pharmaceuticals LP$337Research paymentCash or cash equivalentFASENRA Biological, RespiratoryA Randomised, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate the Efficacy and Sa2021
2021-10-20Alexion Pharmaceuticals, Inc.$135Research paymentCash or cash equivalentA Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension 2021
2021-10-18Gilead Sciences, Inc.$416,135Research paymentCash or cash equivalentSLE: ELISA and STING Flow Cytometry2021
2021-10-18Limacorporate S.p.A.$50,000Consulting FeeCash or cash equivalentPHYSICA CR Device, Devices2021
2021-10-18Gilead Sciences, Inc.$9,000Research paymentCash or cash equivalentSLE: ELISA and STING Flow Cytometry2021
2021-10-15Smith+Nephew, Inc.$11,377Research paymentCash or cash equivalentOXINIUM Hip Device, Recon HipsA Multi-Center, Randomized Controlled Study of Efficacy and Safety of the OXINIUM DH Total Hip Replacement System in Sub2021
2021-10-15Ortho Development Corporation$755Royalty or LicenseCash or cash equivalentPagoda Device, ORTHOPEDIC DEVICE2021
2021-10-13Takeda Pharmaceuticals U.S.A., Inc.$1,762Research paymentCash or cash equivalentHYQVIA Biological, IMMUNOLOGYTHIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND 2021
2021-10-13Takeda Pharmaceuticals U.S.A., Inc.$745Research paymentCash or cash equivalentHYQVIA Biological, IMMUNOLOGYTHIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND 2021
2021-10-13Takeda Pharmaceuticals U.S.A., Inc.$419Research paymentCash or cash equivalentHYQVIA Biological, IMMUNOLOGYTHIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND 2021
2021-10-08Stryker Corporation$19,065Research paymentCash or cash equivalentTRITANIUM Device, HIPSMAVRIC MAGNETIC RESONANCE IMAGING USED TO STUDY DETAILED BONE APPOSITION AND FIXATION OF THE STRYKER TRIATHLON CEMENTLES2021
2021-10-08Stryker Corporation$19,065Research paymentCash or cash equivalentTRITANIUM Device, HIPSMAVRIC MAGNETIC RESONANCE IMAGING USED TO STUDY DETAILED BONE APPOSITION AND FIXATION OF THE STRYKER TRIATHLON CEMENTLES2021
2021-10-08Stryker Corporation$19,065Research paymentCash or cash equivalentTRITANIUM Device, HIPSMAVRIC MAGNETIC RESONANCE IMAGING USED TO STUDY DETAILED BONE APPOSITION AND FIXATION OF THE STRYKER TRIATHLON CEMENTLES2021
2021-10-08Stryker Corporation$12,710Research paymentCash or cash equivalentTRITANIUM Device, HIPSMAVRIC MAGNETIC RESONANCE IMAGING USED TO STUDY DETAILED BONE APPOSITION AND FIXATION OF THE STRYKER TRIATHLON CEMENTLES2021
2021-10-06Masimo Corporation$3,297Long term medical supply or device loanIn-kind items and servicesSET and rainbow SET Device, Devices2021
2021-10-04UCB SA$12,900Research paymentCash or cash equivalentAN OPEN-LABEL EXTENSION STUDY TO EVALUATE ROZANOLIXIZUMAB IN STUDY PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS2021
2021-10-04Alexion Pharmaceuticals, Inc.$2,281Research paymentCash or cash equivalentA Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension 2021
2021-10-04UCB SA$1,500Research paymentCash or cash equivalentAN OPEN-LABEL EXTENSION STUDY TO EVALUATE ROZANOLIXIZUMAB IN STUDY PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS2021
2021-10-01Boehringer Ingelheim Pharma GmbH & Co.KG$116Research paymentIn-kind items and servicesOFEV Drug, RESPIRATORYExtension2021
2021-09-30EXACTECH, INC.$154,068Royalty or LicenseCash or cash equivalentTRULIANT Device, ORTHOPAEDIC2021
2021-09-30Arthrex, Inc.$10,000Research paymentCash or cash equivalentSHOULDER IMPLANTS FIBERTAK KNOTTED Device, SHOULDER - IMPLANTS - FIBERTAK - KNOTTEDLongitudinal Outcome Assessment of All-Suture Anchor Medial Row Fixation for RCR IICS/2002021
2021-09-30Engage Uni, LLC$4,381Space rental or facility fees (teaching hospital only)Cash or cash equivalentEngage Partial Knee System Device, Recon Knees2021
2021-09-30MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC.$2,750Research paymentCash or cash equivalentSAFETY STUDY OF ORAL EDARAVONE ADMINISTERED IN SUBJECTS WITH ALS2021
2021-09-29Bio-Rad Laboratories, Inc.$799Debt forgivenessCash or cash equivalentSeraclone Anti-A (ABO1) Device, Blood Typing2021
2021-09-27DePuy Synthes Products, Inc.$11,827Royalty or LicenseCash or cash equivalent2021
2021-09-27UOC USA INC$275Consulting FeeCash or cash equivalentU-Motion II, UTF Device, UOC Hip System2021
2021-09-21Orthofix Medical, Inc.$250Research paymentCash or cash equivalentM6-C Device, Prosthesis, Intervertebral DiscM6-C Post Approval Study (PAS)- CA-C0042021
2021-09-20Medical Device Business Services, Inc.$6,861Space rental or facility fees (teaching hospital only)Cash or cash equivalent2021
2021-09-16UCB SA$500Research paymentCash or cash equivalentA PHASE 3, RANDOMIZED, DOUBL-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING EFFICACY AND SAFETY OF ROZANOLIXIZUMAB IN ADULT 2021
2021-09-15Ortho Development Corporation$678Royalty or LicenseCash or cash equivalentPagoda Device, ORTHOPEDIC DEVICE2021
2021-09-14Smith+Nephew, Inc.$6,272Space rental or facility fees (teaching hospital only)Cash or cash equivalent2021
2021-09-14Smith+Nephew, Inc.$5,011Space rental or facility fees (teaching hospital only)Cash or cash equivalent2021
2021-09-14Smith+Nephew, Inc.$4,946Space rental or facility fees (teaching hospital only)Cash or cash equivalentLENS Device, Sports Med Visualization2021
2021-09-14Smith+Nephew, Inc.$4,296Space rental or facility fees (teaching hospital only)Cash or cash equivalentLENS Device, Sports Med Visualization2021
2021-09-14Smith+Nephew, Inc.$4,212Space rental or facility fees (teaching hospital only)Cash or cash equivalentLENS Device, Sports Med Visualization2021
2021-09-14EXACTECH, INC.$2,630Research paymentCash or cash equivalentTRULIANT Device, ORTHOPAEDIC2021
2021-09-14Smith+Nephew, Inc.$2,628Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2021
2021-09-14Takeda Pharmaceuticals U.S.A., Inc.$1,829Research paymentCash or cash equivalentHYQVIA Biological, IMMUNOLOGYTHIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND 2021
2021-09-14Takeda Pharmaceuticals U.S.A., Inc.$1,795Research paymentCash or cash equivalentHYQVIA Biological, IMMUNOLOGYTHIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND 2021
2021-09-14Takeda Pharmaceuticals U.S.A., Inc.$1,716Research paymentCash or cash equivalentHYQVIA Biological, IMMUNOLOGYTHIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND 2021
2021-09-14Smith+Nephew, Inc.$1,060Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentLENS Device, Sports Med Visualization2021
2021-09-14Smith+Nephew, Inc.$878Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentLENS Device, Sports Med Visualization2021
2021-09-14Takeda Pharmaceuticals U.S.A., Inc.$618Research paymentCash or cash equivalentHYQVIA Biological, IMMUNOLOGYTHIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND 2021
2021-09-14Smith+Nephew, Inc.$525Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentLENS Device, Sports Med Visualization2021
2021-09-14Smith+Nephew, Inc.$525Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2021
2021-09-14Takeda Pharmaceuticals U.S.A., Inc.$88Research paymentCash or cash equivalentHYQVIA Biological, IMMUNOLOGYTHIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND 2021
2021-09-14Takeda Pharmaceuticals U.S.A., Inc.$50Research paymentCash or cash equivalentHYQVIA Biological, IMMUNOLOGYTHIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND 2021
2021-09-10Regeneron Pharmaceuticals, Inc.$22,108Research paymentCash or cash equivalentTCR SEQUENCING AND TRANSCRIPTIONAL PROFILING IN HLA B27 ASSOCIATED DISEASE2021
2021-09-09DJO, LLC$18,714GrantCash or cash equivalent2021
2021-09-09Stryker Corporation$500Research paymentCash or cash equivalentTRITANIUM Device, HIPSMAVRIC MAGNETIC RESONANCE IMAGING USED TO STUDY DETAILED BONE APPOSITION AND FIXATION OF THE STRYKER TRIATHLON CEMENTLES2021
2021-09-09Alexion Pharmaceuticals, Inc.$50Research paymentCash or cash equivalentA Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravuli2021
2021-09-08GE HEALTHCARE$23,625Research paymentIn-kind items and servicesDevelopment of Technology to Extend Scope of MRI in Orthopedic2021
2021-09-03Regeneron Pharmaceuticals, Inc.$27,778Research paymentCash or cash equivalentSTUDY TO EVALUATE ARTHROPLASTY SPECIMENS IN THE PHASE 3 FASINUMAB PROGRAM FOR OSTEOARTHRITIS OF THE KNEE AND HIP2021
2021-09-02Kadmon Corporation LLC$40,214Research paymentCash or cash equivalentA Phase 2 Randomized Placebo controlled Double blind Open label Extension Multicenter Study to Evaluate the Efficacy and2021
2021-09-02Stryker Corporation$1,670Research paymentCash or cash equivalentRIO Device, ROBOTICSSURVIVORSHIP AND OUTCOMES OF ROBOTIC ARM ASSISTED MEDIAL UKA2021
2021-09-01Boehringer Ingelheim Pharma GmbH & Co.KG$119Research paymentIn-kind items and servicesOFEV Drug, RESPIRATORYExtension2021
2021-08-31UCB SA$9,500Research paymentCash or cash equivalentPhase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis2021
2021-08-31TREACE MEDICAL CONCEPTS, INC.$4,966Space rental or facility fees (teaching hospital only)Cash or cash equivalentLapiplasty System Device, Y2021
2021-08-31UCB SA$500Research paymentCash or cash equivalentPhase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis2021
2021-08-30UCB SA$40Research paymentCash or cash equivalentA PHASE 3, RANDOMIZED, DOUBL-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING EFFICACY AND SAFETY OF ROZANOLIXIZUMAB IN ADULT 2021
2021-08-26Radius Health, Inc.$90,113Consulting FeeCash or cash equivalent2021
2021-08-26Novartis Pharmaceuticals Corporation$4,350Research paymentCash or cash equivalent BiologicalA RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED MULTICENTER PHASE 2 DOSE RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF2021
2021-08-25Zimmer Biomet Holdings, Inc.$13,325Space rental or facility fees (teaching hospital only)Cash or cash equivalentROSA-Knee Device, Knees2021
2021-08-25Zimmer Biomet Holdings, Inc.$8,775Space rental or facility fees (teaching hospital only)Cash or cash equivalentROSA-Knee Device, Knees2021
2021-08-19Abbott Laboratories$690Debt forgivenessCash or cash equivalent2021
2021-08-19UCB SA$500Research paymentCash or cash equivalentA RANDOMIZED, OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF ROZANOLIXIZU2021
2021-08-18Stryker Corporation$3,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentACCOLADE Device, HIPS2021
2021-08-18Stryker Corporation$3,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentNA Device, ARTHROSCOPY2021
2021-08-18Smith+Nephew, Inc.$1,495Research paymentCash or cash equivalentJOURNEY II BCS Device, Recon KneesA Retro-Prospective, Non-randomized, Consecutive Series, SIngle Cohort, Multicenter Adaptive Design Study to Evaluate th2021
2021-08-18Alexion Pharmaceuticals, Inc.$135Research paymentCash or cash equivalentA Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension 2021
2021-08-17Takeda Pharmaceuticals U.S.A., Inc.$1,575Research paymentCash or cash equivalentHYQVIA Biological, IMMUNOLOGYTHIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND 2021
2021-08-17UCB SA$1,180Research paymentCash or cash equivalentA Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, and Pre2021
2021-08-17UCB SA$50Research paymentCash or cash equivalentA Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, and Pre2021
2021-08-16EXACTECH, INC.$5,739Space rental or facility fees (teaching hospital only)Cash or cash equivalentVANTAGE Device, ORTHOPAEDIC2021
2021-08-15Zimmer Biomet Holdings, Inc.$7,500GrantCash or cash equivalentGrants Device, General2021
2021-08-15Zimmer Biomet Holdings, Inc.$6,436GrantCash or cash equivalentGrants Device, General2021
2021-08-15Zimmer Biomet Holdings, Inc.$5,461GrantCash or cash equivalentGrants Device, General2021
2021-08-15Zimmer Biomet Holdings, Inc.$5,144GrantCash or cash equivalentGrants Device, General2021
2021-08-15Zimmer Biomet Holdings, Inc.$4,734GrantCash or cash equivalentGrants Device, General2021
2021-08-15Zimmer Biomet Holdings, Inc.$4,387GrantCash or cash equivalentGrants Device, General2021
2021-08-15Zimmer Biomet Holdings, Inc.$3,949GrantCash or cash equivalentGrants Device, General2021
2021-08-15Medical Device Business Services, Inc.$1,408GrantCash or cash equivalent2021
2021-08-15Medical Device Business Services, Inc.$791GrantCash or cash equivalent2021
2021-08-15Medical Device Business Services, Inc.$730GrantCash or cash equivalent2021
2021-08-15Medical Device Business Services, Inc.$721GrantCash or cash equivalent2021
2021-08-15Medical Device Business Services, Inc.$697GrantCash or cash equivalent2021
2021-08-15Zimmer Biomet Holdings, Inc.$566GrantCash or cash equivalentGrants Device, General2021
2021-08-15Medical Device Business Services, Inc.$529GrantCash or cash equivalent2021
2021-08-15Medical Device Business Services, Inc.$265GrantCash or cash equivalent2021
2021-08-15KCI USA, Inc.$209GrantCash or cash equivalent2021
2021-08-15KCI USA, Inc.$68GrantCash or cash equivalent2021
2021-08-13Ortho Development Corporation$788Royalty or LicenseCash or cash equivalentPagoda Device, ORTHOPEDIC DEVICE2021
2021-08-12Stryker Corporation$582Research paymentCash or cash equivalentTRITANIUM Device, HIPSTRIDENT II TRITANIUM OUTCOMES STUDY2021
2021-08-12Stryker Corporation$528Research paymentCash or cash equivalentSECUR-FIT Device, HIPSSECURFIT ADVANCED OUTCOMES STUDY2021
2021-08-12Stryker Corporation$250Research paymentCash or cash equivalentRESTORATION Device, HIPSRESTORATION; ANATOMIC DUAL MOBILITY (ADM) X3; ACETABULAR SYSTEM STUDY WITH LONG TERM DATA COLLECTION FOR THE ACCOLADE; I2021
2021-08-11Alexion Pharmaceuticals, Inc.$1,978Research paymentCash or cash equivalentA Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension 2021
2021-08-09DePuy Synthes Products, Inc.$10,712Space rental or facility fees (teaching hospital only)Cash or cash equivalentRECLAIM Device, Ortho-Hip2021
2021-08-09DePuy Synthes Products, Inc.$10,712Space rental or facility fees (teaching hospital only)Cash or cash equivalentRECLAIM Device, Ortho-Hip2021

The latest 200 records of 447.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Kings CountyNew York city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In New York, NY, county Kings County, NY, state New York; placed by its city name.

MeasurePlace (city or town)
New York, NY
County
Kings County, NY
State
New York
Population B010038,483,8442,631,58019,852,366
Population, 2020 census P18,804,1902,736,07420,201,249
Median age B0100238.236.539.8
Under 18 B0100120.2%22.2%20.5%
65 and over B0100116.6%15.5%17.9%
Households B110013,334,0881,009,9277,722,646
Foreign born B0500236.6%35.3%22.8%
Median household income B19013$80,483$80,263$85,974
Median family income B19113$91,707$88,947$106,873
Per capita income B19301$51,844$47,575$50,712
Poverty rate B1700117.9%19.1%14.0%
Unemployment rate B230258.0%7.9%6.4%
Civilian labor force B230254,392,2971,353,36110,171,766
Mean commute (minutes) B0801340.341.732.6
Bachelor's degree or higher B1500341.6%42.1%40.2%
Housing units B250013,678,4861,100,7728,585,241
Owner-occupied B2500332.8%29.5%54.3%
Renters B2500367.2%70.5%45.7%
Median home value B25077$777,600$905,000$423,800
Median gross rent B25064$1,821$1,833$1,621
White, not Hispanic B0300231.0%36.1%52.8%
Black B0300220.4%26.6%13.4%
Hispanic or Latino B0300228.5%19.0%19.8%
Asian B0300214.6%12.1%9.0%
American Indian and Alaska Native B030020.2%0.1%0.2%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in New York, NY.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.